Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.6 (
chymopapain
)
407
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of
chymopapain
treatment of the canine intervertebral disc were studied in vivo by monitoring proteoglycan in the nucleus pulposus. Analysis of proteoglycan was carried out by Sepharose CL-4B (Pharmacia Fine Chemicals AB, Stockholm, Sweden) chromatography and electrophoresis. The proteoglycan was degraded to glycosaminoglycans within 1 week after
chymopapain
treatment. Two weeks later, a proteoglycan smaller than the original appeared in the nucleus pulposus. At 8 weeks after injection, the amount of the newly synthesized proteoglycan, similar in molecular weight to the original, had recovered to about half that of the original, although the new proteoglycan fraction was rich in
hyaluronic acid
. It was concluded that, following chemonucleolysis with
chymopapain
, the water-binding capacity of the nucleus pulposus recovered, but that the regenerated nucleus pulposus differed biochemically from the original.
...
PMID:Degradation and biosynthesis of proteoglycans in the nucleus pulposus of canine intervertebral disc after chymopapain treatment. 320 93
